GHX Announces Agreement to Acquire Majority of Assets of Medical Columbus
Global Healthcare Exchange (GHX), a leader in cloud-based healthcare supply chain management solutions, today announced that it has entered into an agreement to acquire a majority of the assets and employees of Germany-based Medical Columbus AG, a provider of healthcare procurement software for providers and suppliers across Germany, Switzerland, Austria, Luxembourg, and the Netherlands. The acquisition expands GHX’s European supply chain and procurement products portfolio to deliver even greater efficiency and value to the healthcare community. The acquisition is expected to close in about three months.
Both companies’ solutions serve providers, suppliers and group purchasing organizations (GPOs) in healthcare. The combined product offering gives GHX the ability to expand its procurement solutions offering and its trading partner network in key markets in Europe while helping to deliver operational efficiencies for both providers and suppliers in Germany, Switzerland, Austria, Luxembourg and the Netherlands. GHX has been operating in Europe since 2000.
“The solutions and employee team we are acquiring is a tremendous addition to GHX Europe,” said Bruce Johnson, CEO and president of GHX. “With this acquisition, we are enhancing our solutions portfolio and expanding our footprint in Europe. This is great for our multi-national suppliers and local European provider customers by providing them with a larger pool of potential trading partners that can fuel increased business process efficiencies.”
Added Dirk Isenberg, CEO at Medical Columbus, “We are pleased to be joining with GHX to help drive down costs in healthcare, allowing our customers access to best of breed e-catalogue and e-procurement solutions.”
With more than 4,000 hospitals and 18,000 provider facilities worldwide in the GHX community, the acquisition reinforces GHX’s commitment to remove cost from healthcare by continuing to grow a global trading partner network that benefits both provider and suppliers.
ABOUT MEDICAL COLUMBUS
Founded in 1998, Medical Columbus is one of the e-health pioneers focusing on procurement processes. The company's transaction platform synchronizes the various IT systems and catalog data from medical device, pharmaceutical industry, and hospital customers. By standardizing data and processes, mistakes are avoided, processing times are shortened, and costs for suppliers and providers are significantly reduced. Medical Columbus products are best of breed in modern healthcare supply chain solutions. For more information, visit www.medicalcolumbus.de.
ABOUT GHX EU
Global Healthcare Exchange, LLC (GHX) is a healthcare and data automation company, empowering healthcare organizations to enable better patient care and maximize savings using its world-class cloud-based supply chain technology platform, solutions, analytics and services. GHX brings together healthcare providers, manufacturers and distributors in North America, and Europe, who rely on smart, secure healthcare-focused technology and comprehensive data to automate business processes and make more informed, timely and fact-based decisions. Solutions span procurement and accounts payable automation, contract and inventory management, vendor credentialing and management, business intelligence, payment management and other supply chain-related tools and services. For more information, visit www.ghx.com/europe/en (Europe), www.ghx.com (North America), and The Healthcare Hub blog.
Viktoria Skrzypek, +49 (0) 341 870 98 4-38
GHX North America:
Tier One Partners
Kathy Wilson, 781-652-0499
Dirk Isenberg, +49 (0) 6174 9617 18
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Full Core of Westinghouse Fuel Achieved at South-Ukraine Nuclear Power Plant Unit 319.7.2018 13:25 | Pressemelding
Westinghouse Electric Company announced today that Ukraine’s State Enterprise National Nuclear Energy Generation Company (SE NNEGC) Energoatom’s South-Ukraine NPP Unit 3 near Yuzhnoukrainsk in Mykolaiv province was loaded with a full core of Westinghouse VVER-1000 fuel. This is the first unit in Ukraine to operate with Westinghouse VVER-1000 fuel assemblies as the sole fuel source. “Westinghouse began supplying fuel to Ukraine in 2005, when the first lead test assemblies were delivered to South-Ukraine Unit 3,” said Aziz Dag, vice president and managing director, Northern Europe. “We are proud to continue supporting Ukraine with their energy diversification by supplying a full core of Westinghouse VVER-1000 fuel to our customer, Energoatom.” Westinghouse currently supplies fuel to six of Ukraine’s 15 nuclear power reactors. Beginning in 2021, the number of reactors with Westinghouse fuel will increase to seven. “Westinghouse has made significant investments over the last several years
Seoul Semiconductor Delivers Its Innovative LED "SunLike" to U.S. Lighting Market19.7.2018 13:00 | Pressemelding
Seoul Semiconductor Co., Ltd. (KOSDAQ:046890), a market leader in LED (light emitting diode) design and manufacturing, announced that its innovative LED “SunLike” is applied to brand new lightings to be launched by three lighting premium brands in U.S., Pure Edge Lighting, LEDRAbrands, Inc. and Elite Lighting. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180719005377/en/ The product of LEDRAbrands, Inc., NU4RA-SUN, which applied SunLike of Seoul Semiconductor (Photo: Business Wire) Seoul Semiconductor supplies SunLike to pendant lighting for Pure Edge, a U.S. lighting solution company. It is applied to high-end lighting for museums and art galleries that require the highest color quality. The leading lighting design companies, LEDRAbrands, Inc. and Elite Lighting, apply SunLike to downlights and spotlights respectively. “We have selected Seoul Semiconductor’s innovative LED SunLike for our human centric lighting and believ
Kite and Gadeta Announce Strategic Collaboration to Advance Gamma Delta T Cell Receptor Technology for Solid Tumors19.7.2018 12:30 | Pressemelding
Kite, a Gilead Company (Nasdaq: GILD), and Gadeta B.V., a privately-held company focused on the discovery and development of novel cancer immunotherapies based on gamma delta T cell receptors (TCRs), have entered into a strategic collaboration to develop novel gamma delta TCR therapies in various cancers. Under the financial terms, Kite will provide research and development (R&D) funding for the collaboration and Gadeta will be eligible to receive future payments upon achievement of certain regulatory milestones. In addition, Kite will make an upfront purchase of equity in Gadeta from Gadeta’s shareholders and may acquire additional equity in Gadeta upon achievement of certain R&D milestones. Kite will have the exclusive option to acquire Gadeta. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180719005418/en/ Gadeta has developed a proprietary technology to engineer alpha beta T cells with gamma delta TCRs, called TEGs, for
Boehringer Ingelheim and Lilly announce Trajenta®’s CARMELINA® cardiovascular outcome trial met its primary endpoint19.7.2018 12:08 | Pressemelding
CARMELINA®1 (CArdiovascular safety and Renal Microvascular outcomE with LINAgliptin in patients with type 2 diabetes at high vascular risk) met its primary endpoint, defined as time to first occurrence of cardiovascular death, non-fatal myocardial infarction or non-fatal stroke (3-point MACE), with Trajenta® (linagliptin) demonstrating similar cardiovascular safety compared to placebo. Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) announced today positive top-line results, which evaluated the impact of treatment with linagliptin vs. placebo on cardiovascular safety on top of standard of care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180719005409/en/ The study included 6,979 adults with type 2 diabetes and high cardiovascular risk.1 The majority of patients also had kidney disease, an important risk factor for cardiovascular disease. The overall safety profile of linagliptin in CARMELINA®, including adults
Tradeshift Announces Q2 2018 Results19.7.2018 11:00 | Pressemelding
Tradeshift, the leader in supply chain payments and marketplaces, today announced results from the second quarter of 2018, showing significant momentum across the company. Tradeshift’s second quarter growth stats announced today include: YoY new bookings grew 315% YoY gross merchandise volume (GMV) grew 350% Largest deal in the quarter was $18.6M Tradeshift’s customer roster showed remarkable growth this quarter, adding 38 new customers, including several Fortune 500 companies such as one of the world’s leading innovators in materials science, the endurance challenge event leader, and the world’s leading platform for clinical development, commercial and real-world data analytics. “It’s amazing to see our strategy work across all areas of our business,” said Christian Lanng, CEO and co-founder of Tradeshift. “We took a big bet that the industry was ready for innovation, and we’re proud that some of the largest companies in the world are now part of the momentum we’re seeing across every
JPMorgan Chase Bank announces the initial exchange price for the cash-settled exchangeable bonds into Ping An Insurance (Group) Company of China Limited due 202019.7.2018 10:58 | Pressemelding
NOT FOR DISTRIBUTION IN OR INTO THE UNITED STATES OR TO, OR FOR THE ACCOUNT OR BENEFIT OF, U.S. PERSONS (AS DEFINED IN REGULATION S UNDER THE U.S. SECURITIES ACT OF 1933) OR IN OR INTO JAPAN, THE PEOPLE’S REPUBLIC OF CHINA, SWITZERLAND OR ANY OTHER JURISDICTION IN WHICH SUCH DISTRIBUTION WOULD BE PROHIBITED BY APPLICABLE LAW. Following the placement on 17 July 2018, JPMorgan Chase Bank, N.A. today announces the initial exchange price of the cash-settled exchangeable bonds due 2020 (the “Bonds”) in aggregate principal amount of USD 350 million, referable to H-shares of Ping An Insurance (Group) Company of China Limited (the “Shares”). The initial exchange price of the Bonds has been set at HKD82.1720, representing a 16% premium over the share reference price of HKD70.8379, which was determined in the manner described in the press announcements released on 17 July 2018. Settlement and delivery of the Bonds is expected to take place on 20 July 2018. The Bonds are expected to be rated “Aa3